IGC Strangle Strategy
IGC (IGC Pharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on AMEX.
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
IGC (IGC Pharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $29.2M, a beta of 0.50 versus the broader market, a 52-week range of 0.24-0.5, average daily share volume of 1.1M, a public-listing history dating back to 2006, approximately 67 full-time employees. These structural characteristics shape how IGC stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.50 indicates IGC has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on IGC?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current IGC snapshot
As of May 15, 2026, spot at $0.29, ATM IV 27.10%, IV rank 2.03%, expected move 7.77%. The strangle on IGC below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on IGC specifically: IGC IV at 27.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a IGC strangle, with a market-implied 1-standard-deviation move of approximately 7.77% (roughly $0.02 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IGC expiries trade a higher absolute premium for lower per-day decay. Position sizing on IGC should anchor to the underlying notional of $0.29 per share and to the trader's directional view on IGC stock.
IGC strangle setup
The IGC strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IGC near $0.29, the first option leg uses a $0.30 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IGC chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IGC shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $0.30 | N/A |
| Buy 1 | Put | $0.28 | N/A |
IGC strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
IGC strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on IGC. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on IGC
Strangles on IGC are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IGC chain.
IGC thesis for this strangle
The market-implied 1-standard-deviation range for IGC extends from approximately $0.27 on the downside to $0.31 on the upside. A IGC long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IGC IV rank near 2.03% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IGC at 27.10%. As a Healthcare name, IGC options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IGC-specific events.
IGC strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IGC positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IGC alongside the broader basket even when IGC-specific fundamentals are unchanged. Always rebuild the position from current IGC chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on IGC?
- A strangle on IGC is the strangle strategy applied to IGC (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IGC stock trading near $0.29, the strikes shown on this page are snapped to the nearest listed IGC chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are IGC strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IGC strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 27.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IGC strangle?
- The breakeven for the IGC strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IGC market-implied 1-standard-deviation expected move is approximately 7.77%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on IGC?
- Strangles on IGC are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IGC chain.
- How does current IGC implied volatility affect this strangle?
- IGC ATM IV is at 27.10% with IV rank near 2.03%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.